NRx Pharmaceuticals, Inc.
NASDAQ:NRXPBiotechnology
+$0.06 today
- Market cap
- $124.12M
- Beta
- 2.19
- P/E (TTM)
- -5.3
- EPS (TTM)
- -$0.76
Volume 2.09M
Average 1.27M
NRXP Net Income
Bottom-line profit, the starting point for calculating cash from operations.
NRx Pharmaceuticals, Inc.NASDAQ: NRXP
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income dips below year-ago levels
Q1 FY2026 net income of $1.43M (cash outflow) fell 74.1% year over year, behind the +1.8% change in trailing-twelve-month net income. Over 3 fiscal years it compounded at -10.4% a year.
Context
- Net income amounted to 2336.5% of revenue in FY2025.
- Net income grew in size in 1 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 3 analysts of -$18.14M (-36.6%) for the fiscal year ending Dec 2026, a slowdown from the +13.9% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$1.43M-497.2% QoQ
- Last fiscal yearDec 2025
- -$28.62M+13.9% YoY
- LTMMar 2026
- -$24.54M+1.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -74.1% | -73.8% | +0.3 pp |
| 1 year | +13.9% | -36.6% | -50.5 pp |
| 3-year CAGR | -10.4% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (28.62M) USD
- Year-over-year change
- -13.9%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (28.62M) | -13.9% |
| FY2024 | 2024-12-31 | (25.13M) | +16.7% |
| FY2023 | 2023-12-31 | (30.15M) | +24.2% |
| FY2022 | 2022-12-31 | (39.75M) | +57.3% |
| FY2021 | 2021-12-31 | (93.06M) | — |
Net Income vs competitors
How NRXP compares with its peers on the latest reported figures
- NRXP's LTM Mar 2026 net income of $24.54M is the 6th largest of the 9 companies compared; the peer median is $35.9M.
- Its year-over-year change of +1.8% is the 5th highest of 9, against a peer median of -10.2%.
- Net income amounts to 1070.2% of revenue for NRXP, versus a peer median of 164.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $194.97M | +211.8% | +5.9% | 129.0% | |
| LTM Mar 2026 | $107.79M | +391.1% | -58.2% | — | |
| LTM Mar 2026 | $60.96M | -388.6% | -1.9% | 18297.5% | |
| LTM Mar 2026 | $37.19M | -32.9% | -5.5% | — | |
| LTM Jun 2026 | $34.61M | -52.7% | +4.2% | 164.8% | |
| LTM Mar 2026 | $24.54M | +1.8% | -10.4% | 1070.2% | |
| LTM Mar 2026 | $19.52M | -51.9% | -20.5% | 59.6% | |
| LTM Mar 2026 | $19.06M | +36.2% | -28.9% | — | |
| LTM Mar 2026 | $12.72M | +12.6% | -31.8% | 899.5% | |
| Peer median (excluding NRXP) | $35.9M | -10.2% | -13.0% | 164.8% | |
Competitors are the stored peer set for NRXP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (93.06M) | (39.75M) | (30.15M) | (25.13M) | (28.62M) |
| Depreciation & Amortization | 2K | 4K | 5K | 5K | 143K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 7.79M | 3.63M | 387K | 486K | 228K |
| Change in Working Capital | (4.9M) | 699K | 5.16M | 5.29M | 1.41M |
| Accounts Receivables | 831K | 0 | 0 | 0 | 48K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (19K) | (1.61M) | 2.66M | (5.22M) | 113K |
| Other Working Capital | (5.71M) | 2.31M | 2.51M | 10.51M | 1.25M |
| Other Non-Cash Items | 52.47M | (4.33M) | 2.94M | 8.71M | 12.73M |
| Operating Cash Flow | (37.7M) | (39.76M) | (21.66M) | (10.64M) | (14.11M) |
| Capital Expenditures | (7K) | (10K) | (3K) | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | (2.38M) |
| Purchases of Investments | 0 | 0 | 0 | 0 | (432K) |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (7K) | (10K) | (3K) | 0 | (2.81M) |
| Debt Repayment | (1.28M) | 9.5M | (3.09M) | (1.5M) | 7.42M |
| Common Stock Issued | 36.98M | 22.7M | 8.12M | 5.91M | 15.86M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 27.75M | 10K | 0 | 3.07M | 0 |
| Financing Cash Flow | 63.46M | 32.21M | 6.2M | 7.49M | 23.28M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 25.75M | (7.55M) | (15.46M) | (3.15M) | 6.35M |
| Free Cash Flow | (37.71M) | (39.77M) | (21.66M) | (10.64M) | (14.11M) |
NRx Pharmaceuticals, Inc.
NASDAQ:NRXP
Intrinsic Alpha fair value
Locked
Current Price
$2.80
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.